Probiotic composition for relieving allergic symptoms and application thereof
Probiotic compositions, including probiotics such as Lactobacillus acidophilus and Lactobacillus planta, combined with ingredients such as prebiotics and polysaccharides, are solved, and the problem of slow and unstable allergic symptoms is solved. , achieved rapid onset and long-term maintenance of allergic symptoms, and significantly improved the symptoms of allergic diseases in children.
Patent Information
- Application Number
- CN202411224832.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-06
AI Technical Summary
Existing probiotic products have slow effect and unstable effects in alleviating allergic symptoms in infants and young children. They cannot be maintained for a long time and cannot effectively solve the problem of treatment of allergic diseases in children.
A probiotic composition is provided, comprising probiotics, prebiotics and Lactobacillus plantarum epibiotics, specifically Lactobacillus acidophilus and Lactobacillus plantarum, combining polysaccharides and broccoli powder through specific viable bacteria ratios and auxiliary material ratios. , make oral preparations in the form of powders and other oral preparations, which are used to relieve allergic reactions and repair damaged mucosa.
Achieve rapid onset and long-term stable allergic symptoms relief effect, improve immunity, and significantly improve the symptoms of allergic diseases. Especially when combined with ivy extract and yeast-β-glucan, the effect is more significant .
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of probiotic supplements, and in particular to a probiotic composition for relieving allergic symptoms and uses thereof. Background Art
[0002] Probiotics are a type of active microorganisms that are beneficial to the host by colonizing in the human body and changing the composition of the flora in a certain part of the host. They promote nutrient absorption and maintain intestinal health by regulating the host mucosal and systemic immune functions or by regulating the balance of intestinal flora, thus producing single microorganisms or mixed microorganisms with clear composition that are beneficial to health.
[0003] Allergy is a pathological immune response. With the global prevalence increasing year by year, it has become a common disease that troubles human health. Currently, most treatments for allergic diseases have little effect. Studies have confirmed that probiotics can stimulate the immunoregulatory properties of immune cells, maintain the balance of the immune environment, and regulate the gastrointestinal ecosystem. They are potential effective treatments for allergic diseases.
[0004] There are several anti-allergic mechanisms of probiotics: First, probiotics can regulate intestinal mucosal immunity. Probiotics can enhance the barrier function of mucosal cells by regulating tight junctions between intestinal epithelial cells. For example, Streptococcus thermophilus and Lactobacillus acidophilus can promote the phosphorylation of tight junction proteins and cytoskeletal proteins in mucosal cells; Lactobacillus rhamnosus CG can affect the body's autoimmune response by regulating dendritic cell function. Probiotics can also activate local giant cells, regulate the production of local and systemic IgA, and change the pro-inflammatory and anti-inflammatory cytokine spectrum, thereby regulating the response to food antigens. Other studies have shown that probiotics can improve intestinal barrier function, thereby affecting the intestinal microenvironment and immune system and reducing the risk of allergies. Secondly, probiotics can promote Th1-type immune responses and inhibit Th2-type immune responses by inducing immune cells to release cytokines and changing the Th1 / Th2 balance. In addition, it is possible to regulate immune responses by enhancing the advantages of Treg.
[0005] The intestinal microbiota plays an important role in the establishment and maturation of the host immune system. In recent years, studies have found that the imbalance of intestinal microecology is related to the occurrence and development of allergic diseases in children. Probiotics have the effect of improving intestinal microecological imbalance, and their relationship with the prevention and treatment of allergic diseases is a current research hotspot. This article reviews the research progress on intestinal microbiota and children's allergic diseases, the immunomodulatory mechanism of probiotics in rebalancing intestinal microecology, and Lactobacillus paracasei and allergic diseases (such as atopic dermatitis, allergic rhinitis, and bronchial asthma).
[0006] There are many probiotic products on the market that can be used to relieve allergies in infants and young children, but they are slow to take effect and can only provide temporary relief and cannot maintain long-term stable effects. Summary of the invention
[0007] In a first aspect, the present invention provides a probiotic composition comprising probiotics, prebiotics, and Lactobacillus plantarum postbiotics.
[0008] In some embodiments, probiotics include but are not limited to Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus delbrueckii subsp. lactis, Bifidobacterium longum subsp. longum, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium animalis subsp. lactis, Bifidobacterium adolescentis, Lactobacillus rhamnosus, Lactobacillus mucilaginosus reuteri, Lactobacillus mucilaginosus fermentum, Lactobacillus plantarum, Lactobacillus paracasei, and Saccharomyces boulardii.
[0009] In some embodiments, the probiotics in the composition are Lactobacillus plantarum and Lactobacillus acidophilus.
[0010] In some embodiments, the Lactobacillus plantarum postbiotic in the composition is heat-killed Lactobacillus plantarum, Lactobacillus plantarum lysate, or a culture solution containing dead cells of Lactobacillus plantarum, preferably heat-killed Lactobacillus plantarum.
[0011] In some embodiments, the prebiotics in the composition include but are not limited to fructooligosaccharides, galacto-oligosaccharides, isomaltooligosaccharides, inulin oligosaccharides, soy oligosaccharides, and pine oligosaccharides.
[0012] In some embodiments, the total number of probiotics and the mass ratio of postbiotics to prebiotics in the composition are 30-45 billion: 5-25 mg: 100-700 mg, preferably 40-30 billion: 10-20 mg: 100-700 mg, and further preferably 50-15 billion: 10-20 mg: 100-700 mg.
[0013] In some embodiments, the ratio of the number of viable Lactobacillus plantarum to that of Lactobacillus acidophilus in the composition is 1:1-100, preferably 1:1-75, and further preferably 1:1-50.
[0014] In some embodiments, each 1 gram portion of the product contains 3-45 billion live probiotic bacteria, preferably 4-30 billion, and more preferably 5-15 billion.
[0015] In some embodiments, each 1 gram serving of the product contains 1 to 5 billion viable Lactobacillus plantarum cells;
[0016] In some embodiments, each 1 gram serving of the product contains 5.0-9.9 billion viable Lactobacillus plantarum cells;
[0017] In some embodiments, each 1 gram portion of the product contains 5-25 mg, preferably 10-20 mg, of postbiotics.
[0018] In some embodiments, each 1 gram serving of the product contains 100-700 mg of prebiotics.
[0019] In some embodiments, the composition further comprises a polysaccharide.
[0020] In some embodiments, the polysaccharide in the composition includes, but is not limited to, starch, glycogen, cellulose, curdlan, and yeast-β-glucan.
[0021] In some embodiments, the mass ratio of polysaccharide to prebiotic in the composition is 3-135:10-70, preferably 4-45:10-70, and further preferably 5-15:10-70.
[0022] In some embodiments, each 1 gram portion of the product contains 5-600 mg, preferably 25-300 mg, and more preferably 50-150 mg of probiotics.
[0023] In some embodiments, the composition further comprises broccoli pollen.
[0024] In some embodiments, the mass ratio of broccoli pollen to prebiotics in the composition is 2.4-54:100-700, preferably 3.2-18:100-700, and further preferably 4-6:100-700.
[0025] In some embodiments, each 1 gram portion of the product contains 2.4-54 mg, preferably 3.2-18 mg, and more preferably 4-6 mg, of broccoli pollen.
[0026] In a second aspect, the present invention provides a product comprising the composition according to any one of claims 1 to 11 and a pharmaceutically acceptable excipient.
[0027] In some embodiments, the product can be made into powder, tablet, capsule, oral liquid, suspension, jelly candy, crystal ball.
[0028] In some embodiments, the product may be formulated as a powder.
[0029] In some embodiments, the powder comprises the composition of any one of claims 1-11 and bamboo extract powder.
[0030] In some embodiments, the powder further comprises one or a combination of sorbitol, maltitol, mannitol, erythritol, steviol glycosides, and erythritol.
[0031] In some embodiments, the powder further comprises one or a combination of citric acid, fruit acid, malic acid, acetic acid, sodium citrate, and potassium citrate.
[0032] In some embodiments, the powder further comprises one or a combination of pear juice powder, watermelon juice powder, grapefruit powder, strawberry juice powder and cherry juice powder.
[0033] In some embodiments, natural strawberry flavor powder is also included.
[0034] In some embodiments, the preparation method of the powder of the present invention is to grind the above-mentioned various components into powders, mix them, and then fill them into strip bags to obtain the product.
[0035] In a third aspect, the composition or product provided by the present invention is used for relieving allergic reactions, repairing damaged mucosa, and enhancing immunity.
[0036] In a fourth aspect, the composition provided by the present invention is used in combination with a composition prepared from ivy extract and yeast-β-glucan.
[0037] In some embodiments, the combination method is to first take the ivy extract and the yeast-β-glucan composition, and then take the composition of the present invention.
[0038] The composition of the present invention is taken orally directly.
[0039] The composition of the present invention is applicable to people over three years old.
[0040] Beneficial effects of the present invention:
[0041] 1. The composition of the present invention is used in combination with the ivy extract and yeast-β-glucan composition previously prepared by the inventor (application number 2024110767460). The composition of ivy extract and yeast-β-glucan can take effect quickly, while the composition provided by the present invention can achieve a long-term stable effect.
[0042] 2. When producing powder, adding bamboo extract powder can increase the fluidity of the powder, making the various ingredients more evenly mixed, avoiding excessive or insufficient local medication, which affects the efficacy; at the same time, powder with good fluidity can avoid external influences such as temperature and pressure to maintain the stability and effectiveness of the drug. DETAILED DESCRIPTION
[0043] In order to facilitate the understanding of those skilled in the art, the present invention is further described below in conjunction with embodiments, and the contents mentioned in the implementation modes are not intended to limit the present invention.
[0044] Example 1
[0045] Probiotics (the total number of live bacteria of Lactobacillus plantarum LP90 and Lactobacillus acidophilus GM080 is 10 billion), heat-killed Lactobacillus plantarum L-13715 mg, yeast-β-glucan 100 mg, oligofructose (prebiotic) 390 mg, broccoli pollen 5 mg, bamboo extract powder and other auxiliary materials in appropriate amounts are made into 1g strips.
[0046] Example 2
[0047] Probiotics (Lactobacillus plantarum LP90, Lactobacillus acidophilus GM080 total viable bacteria 15 billion), heat-killed Lactobacillus plantarum L-13720 mg, yeast-β-glucan 50 mg, oligofructose (prebiotic) 188.5 mg, broccoli pollen 4 mg, bamboo extract powder and other excipients in appropriate amounts, made into 1g strips.
[0048] Example 3
[0049] Probiotics (the total number of live bacteria of Lactobacillus plantarum LP90 and Lactobacillus acidophilus GM080 is 5 billion), heat-killed Lactobacillus plantarum L-137 10 mg, yeast-β-glucan 150 mg, oligofructose (prebiotic) 591.5 mg, broccoli pollen 6 mg, bamboo extract powder and other auxiliary materials as appropriate, are made into 1g strips.
[0050] Example 4
[0051] Probiotics (the total number of live bacteria of Lactobacillus plantarum LP90 and Lactobacillus acidophilus GM080 is 12.8 billion), 12.5 mg of heat-killed Lactobacillus plantarum L-137, 50 mg of yeast-β-glucan, 300 mg of oligofructose (prebiotic), 4 mg of broccoli pollen, bamboo extract powder and other auxiliary materials are made into 1g strips.
[0052] Example 5
[0053] Probiotics (the total number of live bacteria of heat-killed Lactobacillus plantarum LP90, Lactobacillus acidophilus GM080 and Lactobacillus plantarum L-137 is 6.8 billion), heat-killed Lactobacillus plantarum L-137 22.5 mg, yeast-β-glucan 150 mg, oligofructose (prebiotic) 500 mg, broccoli pollen 6 mg, bamboo extract powder and other excipients are made into 1g strips.
[0054] Comparative Example 1
[0055] Probiotics (the total number of live bacteria of Lactobacillus plantarum LP90 is 10 billion), yeast-β-glucan 100mg, oligofructose (prebiotic) 390mg, broccoli pollen 5mg, bamboo extract powder and other auxiliary materials as appropriate, are made into 1g strips.
[0056] Comparative Example 2
[0057] Probiotics (the total number of live bacteria of Lactobacillus acidophilus GM080 is 10 billion), yeast-β-glucan 100mg, oligofructose (prebiotic) 390mg, broccoli pollen 5mg, bamboo extract powder and other auxiliary materials as appropriate, made into 1g strip pack.
[0058] Comparative Example 3
[0059] 15 mg of heat-killed Lactobacillus plantarum L-137, 100 mg of yeast-β-glucan, 390 mg of oligofructose (prebiotic), 5 mg of broccoli pollen, bamboo extract powder and other auxiliary materials are made into 1g strips.
[0060] Comparative Example 4
[0061] Probiotics (the total number of live bacteria of Lactobacillus plantarum LP90 and Lactobacillus acidophilus GM080 is 10 billion), 15 mg of heat-killed Lactobacillus plantarum L-137, 490 mg of oligofructose (prebiotic), 5 mg of broccoli pollen, bamboo extract powder and other auxiliary materials are made into 1g strips.
[0062] Comparative Example 5
[0063] Probiotics (the total number of live bacteria of Lactobacillus plantarum LP90 and Lactobacillus acidophilus GM080 is 10 billion), 15 mg of heat-killed Lactobacillus plantarum L-137, 490 mg of yeast-β-glucan, 5 mg of broccoli pollen, bamboo extract powder and other auxiliary materials are made into 1g strip packs.
[0064] Comparative Example 6
[0065] Probiotics (the total number of live bacteria of Lactobacillus plantarum LP90 and Lactobacillus acidophilus GM080 is 10 billion), 15 mg of heat-killed Lactobacillus plantarum L-137, 100 mg of yeast-β-glucan, 390 mg of oligofructose (prebiotic), 5 mg of broccoli pollen, without adding bamboo extract powder, are added with appropriate amounts of other auxiliary materials to make a 1g strip bag.
[0066] Example 6 Allergic mouse experiment
[0067] A BALB / c mouse oral whey protein sensitization model was established, 40 male BALB / c mice, 6-8 weeks old, weighing 18-22g, a total of 8 groups, negative control group, positive control group (whey sensitization), Example 1 group, Comparative Example 1 group, Comparative Example 2 group, Comparative Example 3 group, Comparative Example 4 group, Comparative Example 5 group. The mice in the negative control group were gavaged with 200 μL of PBS daily, the mice in the positive control group were gavaged with 200 μL of PBS daily, and 0.2 mL of PBS containing 30 mg of homogenized whey protein and 10 μg of adjuvant MC903 (calcipotriol) was also gavaged daily, and the mice in Example 1 group and Comparative Example 1-5 groups were gavaged with 500 mg / kg of the composition in Example 1 and Comparative Example 1-5, respectively, and 0.2 mL of PBS containing 30 mg of homogenized whey protein and 10 ug of adjuvant MC903 (calcipotriol) was also gavaged daily for 4 weeks. Before stimulation, blood was collected from the canthus and centrifuged to obtain the supernatant. Finally, the mice were gavaged with 0.2 mL of PBS containing 100 mg of whey protein for stimulation. The rectal temperature was measured once 30 minutes before and after gavage. The allergic symptoms were observed 30-60 minutes after gavage and each mouse was scored according to the standards in Table 1 below. The scoring standards are as shown in Table 1.
[0068] Table 1 Mouse allergy symptom scoring table
[0069]
[0070]
[0071] The behavior of the mice was scored, and the score table is shown in Table 2. It can be seen from Table 2 that compared with the model group, the allergic symptoms of the mice taking the composition of the present invention were improved to a certain extent. The score of the Example 1 group was the lowest, between 1-2, and some were even 0, indicating that the allergic symptoms of the mice were well improved, approaching the blank control group; the score range of the comparative examples 1-3 groups was between 4-5, and the comparative examples 1-2 groups had only one probiotic + postbiotic, and the comparative example 3 had only postbiotic, but the allergic symptoms were more serious, indicating that the two probiotics and postbiotics were indispensable, and there may be a certain synergistic effect between them; the scores of the comparative examples 4-5 groups were between 2-4, indicating that in the presence of three bacteria, the overall allergic symptoms were improved, but in the absence of prebiotics or polysaccharides, the effect was worse, which may be that prebiotics or polysaccharides play an auxiliary role in the regulation of bacteria.
[0072] Table 2 Behavioral scores
[0073]
[0074]
[0075] Example 7 Cell experiment & animal experiment: Atopic allergen-induced asthma model in mice
[0076] 1. Cell model: mouse spleen cells
[0077] Experimental scheme: Mouse spleen cells were cultured using a culture medium containing the ivy extract and yeast-β-glucan composition (hereinafter referred to as the combination product) in Example 1 and Patent 2024110767460, and the cell supernatant was taken to evaluate the growth status of Th1 cytokines and the allergic effect of the corresponding combination product on allergic conditions.
[0078] 2. Animal model: Allergic airway inflammation was induced by intraperitoneal injection of 50mcg OVA mixed with Th2 adjuvant aluminum hydroxide; 25mcg OVA was continuously administered during the cycle to maintain the allergic response of mice.
[0079] Experimental plan: Oral gavage of the combination product, detection of plasma immune cell levels to evaluate the effectiveness of the combination product in alleviating allergic airway inflammation.
[0080] Example 8 Allergy test plan
[0081] Samples for trial use: Children over 3 years old and adults with allergic reactions
[0082] Experimental scheme: 5 test subjects were given one sample of the ivy extract and yeast-β-glucan composition in Example 1 and Patent 2024110767460 per day for 6 consecutive days, and the relief of nasal allergic reactions was observed.
[0083] Example 9 Determination of powder fluidity
[0084] The repose angles of the compositions prepared in Examples 1-3 and Comparative Example 6 were measured by the injection method. The repose angle of Example 1 was less than 30°, and its fluidity was the best. The repose angles of Examples 2-3 were between 30 and 40, with little difference. However, the repose angle of Comparative Example 6 was greater than 50%, greater than 45 degrees, and its fluidity was poor.
[0085] Table 3
[0086] sample Angle of repose / ° Example 1 29.72 Example 2 32.14 Example 3 32.89 Comparative Example 6 53.66
[0087] It should be understood that the detailed description of the technical solutions of the present invention by means of the preferred embodiments is illustrative rather than restrictive. A person skilled in the art may modify the technical solutions described in the embodiments, or replace some of the technical features by equivalents, based on reading the specification of the present invention; and these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A probiotic composition for relieving allergies, comprising probiotics, prebiotics, and Lactobacillus plantarum postbiotics.
2. The composition according to claim 1, characterized in that The probiotics are one or a combination of Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus delbrueckii, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium animalis, Bifidobacterium adolescentis, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus paracasei, and Saccharomyces boulardii.
3. The composition according to claim 2, characterized in that The probiotics in the composition are Lactobacillus plantarum and Lactobacillus acidophilus.
4. The composition according to claim 1, characterized in that The Lactobacillus plantarum postbiotic in the composition is heat-killed Lactobacillus plantarum, Lactobacillus plantarum lysate or culture solution containing dead Lactobacillus plantarum cells, preferably heat-killed Lactobacillus plantarum.
5. The composition according to claim 1, characterized in that The prebiotics in the composition are one or more combinations of fructooligosaccharides, galacto-oligosaccharides, isomaltooligosaccharides, inulin oligosaccharides, soybean oligosaccharides and pine oligosaccharides.
6. The composition according to claim 1, characterized in that The total number of probiotics and the mass ratio of postbiotics to prebiotics in the composition are 30-45 billion: 5-25 mg: 100-700 mg, preferably 40-30 billion: 10-20 mg: 100-700 mg, and further preferably 50-15 billion: 10-20 mg: 100-700 mg.
7. The composition according to claim 1, characterized in that The composition further comprises a polysaccharide.
8. The composition according to claim 7, characterized in that The polysaccharide in the composition is one or a combination of starch, glycogen, cellulose, curdlan and yeast-β-glucan.
9. The composition according to claim 7, characterized in that The mass ratio of polysaccharide to prebiotic in the composition is 3-135:10-70, preferably 4-45:10-70, and more preferably 5-15:10-70.
10. The composition according to claim 1, characterized in that The composition also includes broccoli pollen.
11. The composition according to claim 10, characterized in that The mass ratio of broccoli pollen to prebiotics in the composition is 2.4-54:100-700, preferably 3.2-18:100-700, and further preferably 4-6:100-700.
12. A product, characterized in that The invention comprises the composition according to any one of claims 1 to 11 and a pharmaceutically acceptable excipient.
13. The product according to claim 12, characterized in that The product can be made into powder, tablet, capsule, oral liquid, suspension, jelly candy and crystal ball.
14. The product according to claim 13, characterized in that The product can be made into powder.
15. The product according to claim 14, characterized in that The powder comprises the composition according to any one of claims 1 to 11 and bamboo extract powder.
16. The product according to claim 14, characterized in that The powder further comprises one or a combination of sorbitol, maltitol, mannitol, erythritol, steviol glycoside and erythritol.
17. The product according to claim 14, characterized in that The powder further comprises one or a combination of citric acid, fruit acid, malic acid, acetic acid, sodium citrate and potassium citrate.
18. The product according to claim 14, characterized in that The powder further comprises one or a combination of pear juice powder, watermelon juice powder, grapefruit powder, strawberry juice powder and cherry juice powder.
19. The product according to claim 14, characterized in that Also contains natural strawberry flavor powder.
20. Use of the composition according to any one of claims 1 to 11 or the product according to any one of claims 12 to 19 in relieving allergic reactions, repairing damaged mucosa, and enhancing immunity.
21. The use according to claim 20, characterized in that The composition is used in combination with a composition prepared from ivy extract and yeast-β-glucan.
